Urology
Volume 76, Issue 2 , Pages 515.e8-515.e14 , August 2010

Expression of cAMP-dependent Protein Kinase Isoforms in the Human Prostate: Functional Significance and Relation to PDE4

  • Eginhard Waldkirch

      Affiliations

    • Hannover Medical School, Department of Urology and Uro-Oncology, Hannover, Germany
    • ,
  • Stefan Ückert

      Affiliations

    • Hannover Medical School, Department of Urology and Uro-Oncology, Hannover, Germany
    • Corresponding Author InformationReprint requests: Stefan Ückert, Ph.D., Hannover Medical School, Department of Urology and Uro-Oncology, 30623 Hannover, Germany
    • ,
  • Katja Sigl

      Affiliations

    • MorphoSys AG, Martinsried, Germany
    • ,
  • Kristina Langnaese

      Affiliations

    • Otto-von-Guericke-University, Faculty of Medicine, Institute for Biochemistry and Cell Biology, Magdeburg, Germany
    • ,
  • Karin Richter

      Affiliations

    • Otto-von-Guericke-University, Faculty of Medicine, Institute for Biochemistry and Cell Biology, Magdeburg, Germany
    • ,
  • Christian G. Stief

      Affiliations

    • Ludwig-Maximilians-University, Academic Hospital Grosshadern, Department of Urology, Munich, Germany
    • ,
  • Markus A. Kuczyk

      Affiliations

    • Hannover Medical School, Department of Urology and Uro-Oncology, Hannover, Germany
    • ,
  • Petter Hedlund

      Affiliations

    • University Vita San Raffaele, Faculty of Medicine, Department of Urology, Urological Research Institute, Milan, Italy

Received 5 August 2009 ,Accepted 16 April 2010.

References 

  1. Siroky MB. Lower urinary tract symptoms: shifting our focus from the prostate to the bladder. J Urol. 2004;172:1237–1238
  2. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651–659
  3. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10:14–25
  4. Bloch W, Klotz T, Loch C, et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997;33:1–8
  5. Hedlund P, Ekstrom P, Larsson B, et al. Heme oxygenase and NO-synthase in the human prostate—relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst. 1997;63:115–126
  6. Ückert S, Oelke M, Stief CG, et al. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006;49:740–745
  7. Waldkirch E, Ückert S, Langnäse K, et al. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-one in human prostate tissue. Eur Urol. 2007;52:495–502
  8. McVary KT, Monnig W, Camps JL, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177:1071–1077
  9. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401–1407
  10. Stief CG, Porst H, Neuser D, et al. A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53:1236–1244
  11. Guler C, Tuzel E, Dogantekin E, Kiziltepe G. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement?. Urol Int. 2008;80:181–185
  12. Guven EO, Balbay MD, Mete K, Serefoglu EC. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol. 2009;41:287–292
  13. Ückert S, Küthe A, Jonas U, et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 2001;166:2484–2490
  14. Ückert S, Sormes M, Kedia GT, et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology. 2008;71:526–530
  15. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol. 2000;184:409–420
  16. Jackson WF. Rp diastereomeric analogs of cAMP inhibit both cAMP- and cGMP-induced dilation of hamster mesenteric small arteries. Pharmacologist. 1996;52:226–234
  17. Andersson KE. Pharmacology of the lower urinary tract: basis for current and future treatment of urinary incontinence. Pharmacol Rev. 2004;56:581–631
  18. Andersson KE, Ückert S, Stief CG, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007;26:928–933
  19. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155:802–815
  20. Cvijic ME, Kita T, Shih W, et al. Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer. Clin Cancer Res. 2000;6:2309–2317
  21. Kvissel AK, Ramberg H, Eide T, et al. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal. 2007;19:401–409
  22. Sparwasser C, Drescher P, Will JA, et al. Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP- and cyclic GMP-dependent mechanisms. J Urol. 1994;152:2159–2163
  23. Stief CG, Ückert S, Becker AJ, et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology. 2000;55:146–150
  24. Ückert S, Hedlund P, Waldkirch E, et al. Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol. 2004;22:261–266
  25. Haynes JM, Cook AL. Protein kinase G-induced activation of KATP channels reduces contractility of human prostate tissue. Prostate. 2006;66:377–385
  26. Longhurst PA, Briscoe JA, Rosenberg DJ, et al. The role of cyclic nucleotides in guinea-pig bladder contractility. Br J Pharmacol. 1997;121:1665–1672
  27. Gillespie JI. Phosphodiesterase-linked inhibition of non-micturition activity in the isolated bladder. BJU Int. 2004;93:1325–1332
  28. Kaiho Y, Nishiguchi J, Kwon DD, et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int. 2008;101:615–620
  29. Oger S, Behr-Roussel D, Gorny D, et al. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. Eur Urol. 2007;251:772–781

PII: S0090-4295(10)00596-0

doi: 10.1016/j.urology.2010.04.035

Urology
Volume 76, Issue 2 , Pages 515.e8-515.e14 , August 2010

Article Tools

* Image Usage & Resolution